KSSP supports distribution of generic drugs for SMA patients in Keralam

KSSP supports distribution of generic drugs for SMA patients in Keralam left This image is used for representational purpose only.

Getty Images/iStockphoto Getty Images/iStockphoto https://th-i.thgim.com/public/incoming/emandu/article71622825.ece/alternates/FREE_1200/iStock-2247959060.jpg Andrzej Rostek SMA, spinal muscular atrophy.

Health concept.

Text on white blocks.

Blue background, stethoscope.

Incurable diseases.

Copy space.

Close up Kerala Sastra Sahitya Parishad president C.

Ramakrishnan and general secretary V.

Manoj Kumar said that access to this medication is crucial for improving the quality of life and life expectancy of patients Kozhikode The Kerala Sastra Sahitya Parishad (KSSP) has supported the Kerala Health Department’s decision to provide a low-cost generic version of the drug Risdiplam to patients afflicted with Spinal Muscular Atrophy (SMA), a rare and threatening genetic disorder that causes progressive muscle weakness.

What is the controversy over the spinal muscular atrophy drug in Keralam?

Explained What is the controversy over the spinal muscular atrophy drug in Keralam?

Explained After the government switched the drug in its SMA programme from branded to generic, parents of children living with SMA have been asking for a switch back to the branded version; meanwhile the label on a drug bottle has sparked concerns, and political parties have now latched on to the issue What is the controversy over the spinal muscular atrophy drug in Keralam?

Explained storyline 1 In a statement, KSSP president C.

Ramakrishnan and general secretary V.

Manoj Kumar said that access to this medication is crucial for improving the quality of life and life expectancy of patients.

The statement from the pro-Left people’s science movement comes close on the heels of public health experts such as B.

Ekbal, K.

P.

Aravindan, and V.

Ramankutty endorsing the government’s stand.

All you need to know about: Spinal Muscular Atrophy All you need to know about: Spinal Muscular Atrophy Spinal muscular atrophy is a rare inherited neuromuscular disorder caused by changes in the SMN1 gene.

It leads to progressive muscle weakness by affecting the nerve cells that control voluntary movement August: SMA Awareness Month All you need to know about: Spinal Muscular Atrophy storyline 1 The KSSP functionaries pointed out that Natco Pharma is an Indian pharmaceutical company that plays a key role in making affordable cancer treatments more accessible to the general public, both in India and in international markets.

They claimed that the department’s decision is not merely aimed at saving public funds.

It is a humanitarian responsibility to ensure that life-saving treatment is accessible to more SMA patients, they added.